OBJECTIVES: To evaluate the prognostic significance of the total number of lymph nodes obtained at postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). After the multidisciplinary management of metastatic germ cell tumor, approximately 10%-15% of patients with the histologic finding of fibrosis or teratoma will suffer disease recurrence. METHODS: Between 1989 and 2006, a total of 628 patients underwent PC-RPLND and were found to have either fibrosis or teratoma. After Institutional Review Board approval, complete clinical and pathologic data were obtained from our prospective testis cancer surgical database. A Cox proportional hazards regression model was constructed to evaluate the association of the total number of lymph nodes obtained at PC-RPLND on disease recurrence. RESULTS: On pathologic evaluation, 248 (57%) patients had fibrosis and 184 (43%) patients had teratoma. The median number of lymph nodes resected was 25 (interquartile range, 15-37). On multivariable analysis, increasing postchemotherapy nodal size and decreasing lymph node counts were significant predictors of disease recurrence (P=.01, .04, respectively). For patients with 10 nodes removed, the predicted 2-year relapse free probability was 90%, compared with 97% when 50 nodes were removed. CONCLUSIONS: Our data suggest that the total number of lymph nodes removed and analyzed is an independent predictor of disease recurrence after PC-RPLND. This has implications both for the urologist to assure completeness of resection and for the pathologist to meticulously assess the pathologic specimens. Copyright (c) 2010 Elsevier Inc. All rights reserved.
OBJECTIVES: To evaluate the prognostic significance of the total number of lymph nodes obtained at postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). After the multidisciplinary management of metastatic germ cell tumor, approximately 10%-15% of patients with the histologic finding of fibrosis or teratoma will suffer disease recurrence. METHODS: Between 1989 and 2006, a total of 628 patients underwent PC-RPLND and were found to have either fibrosis or teratoma. After Institutional Review Board approval, complete clinical and pathologic data were obtained from our prospective testis cancer surgical database. A Cox proportional hazards regression model was constructed to evaluate the association of the total number of lymph nodes obtained at PC-RPLND on disease recurrence. RESULTS: On pathologic evaluation, 248 (57%) patients had fibrosis and 184 (43%) patients had teratoma. The median number of lymph nodes resected was 25 (interquartile range, 15-37). On multivariable analysis, increasing postchemotherapy nodal size and decreasing lymph node counts were significant predictors of disease recurrence (P=.01, .04, respectively). For patients with 10 nodes removed, the predicted 2-year relapse free probability was 90%, compared with 97% when 50 nodes were removed. CONCLUSIONS: Our data suggest that the total number of lymph nodes removed and analyzed is an independent predictor of disease recurrence after PC-RPLND. This has implications both for the urologist to assure completeness of resection and for the pathologist to meticulously assess the pathologic specimens. Copyright (c) 2010 Elsevier Inc. All rights reserved.
Authors: Alberto Briganti; Felix K-H Chun; Andrea Salonia; Andrea Gallina; Giuseppe Zanni; Vincenzo Scattoni; Luc Valiquette; Patrizio Rigatti; Francesco Montorsi; Pierre I Karakiewicz Journal: Urology Date: 2007-01 Impact factor: 2.649
Authors: John P Stein; David F Penson; Jie Cai; Gus Miranda; Eila C Skinner; Matt A Dunn; Susan Groshen; Gary Lieskovsky; Donald G Skinner Journal: J Urol Date: 2007-03 Impact factor: 7.450
Authors: G C Toner; D M Panicek; R T Heelan; N L Geller; S Y Lin; D Bajorin; R J Motzer; H I Scher; H W Herr; M J Morse Journal: J Clin Oncol Date: 1990-10 Impact factor: 44.544
Authors: Siamak Daneshmand; Marcus L Quek; John P Stein; Gary Lieskovsky; Jie Cai; Jacek Pinski; Eila C Skinner; Donald G Skinner Journal: J Urol Date: 2004-12 Impact factor: 7.450
Authors: Karim Touijer; Farhang Rabbani; Javier Romero Otero; Fernando P Secin; James A Eastham; Peter T Scardino; Bertrand Guillonneau Journal: J Urol Date: 2007-05-11 Impact factor: 7.450
Authors: Bernard H Bochner; Daniel Cho; Harry W Herr; Machele Donat; Michael W Kattan; Guido Dalbagni Journal: J Urol Date: 2004-10 Impact factor: 7.450
Authors: Samuel A Funt; Deaglan J McHugh; Stephanie Tsai; Andrea Knezevic; Devon O'Donnell; Sujata Patil; Deborah Silber; Maria Bromberg; Maryann Carousso; Victor E Reuter; Brett S Carver; Joel Sheinfeld; Robert J Motzer; Dean F Bajorin; George J Bosl; Darren R Feldman Journal: Oncologist Date: 2021-03-12
Authors: Ciğdem Oztürk; Robert J van Ginkel; Ruby M Krol; Jourik A Gietema; Hendrik S Hofker; Harald J Hoekstra Journal: Surg Endosc Date: 2011-09-23 Impact factor: 4.584
Authors: J L H Ruud Bosch; Joost M Blok; Henk G van der Poel; J Martijn Kerst; Axel Bex; Oscar R Brouwer; Simon Horenblas; Richard P Meijer Journal: World J Urol Date: 2020-09-21 Impact factor: 4.226
Authors: J Beyer; P Albers; R Altena; J Aparicio; C Bokemeyer; J Busch; R Cathomas; E Cavallin-Stahl; N W Clarke; J Claßen; G Cohn-Cedermark; A A Dahl; G Daugaard; U De Giorgi; M De Santis; M De Wit; R De Wit; K P Dieckmann; M Fenner; K Fizazi; A Flechon; S D Fossa; J R Germá Lluch; J A Gietema; S Gillessen; A Giwercman; J T Hartmann; A Heidenreich; M Hentrich; F Honecker; A Horwich; R A Huddart; S Kliesch; C Kollmannsberger; S Krege; M P Laguna; L H J Looijenga; A Lorch; J P Lotz; F Mayer; A Necchi; N Nicolai; J Nuver; K Oechsle; J Oldenburg; J W Oosterhuis; T Powles; E Rajpert-De Meyts; O Rick; G Rosti; R Salvioni; M Schrader; S Schweyer; F Sedlmayer; A Sohaib; R Souchon; T Tandstad; C Winter; C Wittekind Journal: Ann Oncol Date: 2012-11-14 Impact factor: 32.976
Authors: Andreas Hiester; Alessandro Nini; Anna Fingerhut; Robert Große Siemer; Christian Winter; Peter Albers; Achim Lusch Journal: Front Surg Date: 2019-01-17